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Abstract
Ewing’s sarcoma family tumors (ESFT) are the second most common bone malignancy in children and young adults,
characterized by unique chromosomal translocations that in 85% of cases lead to expression of the EWS-FLI-1 fusion
protein. EWS-FLI-1 functions as an aberrant transcription factor that can both induce and suppress members of its target
gene repertoire. We have recently demonstrated that EWS-FLI-1 can alter microRNA (miRNA) expression and that miRNA145
is a direct EWS-FLI-1 target whose suppression is implicated in ESFT development. Here, we use miRNA arrays to compare
the global miRNA expression profile of human mesenchymal stem cells (MSC) and ESFT cell lines, and show that ESFT
display a distinct miRNA signature that includes induction of the oncogenic miRNA 17–92 cluster and repression of the
tumor suppressor let-7 family. We demonstrate that direct repression of let-7a by EWS-FLI-1 participates in the tumorigenic
potential of ESFT cells in vivo. The mechanism whereby let-7a expression regulates ESFT growth is shown to be mediated by
its target gene HMGA2, as let-7a overexpression and HMGA2 repression both block ESFT cell tumorigenicity. Consistent with
these observations, systemic delivery of synthetic let-7a into ESFT-bearing mice restored its expression in tumor cells,
decreased HMGA2 expression levels and resulted in ESFT growth inhibition in vivo. Our observations provide evidence that
deregulation of let-7a target gene expression participates in ESFT development and identify let-7a as promising new
therapeutic target for one of the most aggressive pediatric malignancies.
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Introduction
Transformation and subsequent cancer development require
genetic events in the form of point mutation, deletion or
translocation of genes that either promote or control cell growth,
proliferation and survival. The effects of these genetic alterations
are subject to modulation by epigenetic events whose contribution
may be key to the establishment of the full fledged malignant
phenotype. These include promoter methylation of tumor
suppressor genes and histone modifications that regulate DNA
accessibility to transcription factors. More recently, microRNAs
(miRNAs) have been shown to play a major role in potentiating
genetically-driven oncogenic events [1].
MicroRNAs are non-coding transcripts that undergo a defined
series of processing steps, initiated by RNA polymerase II-
mediated transcription to generate a primary miRNA (pri-
miRNA) [1]. Pri-miRNA is processed by the multiprotein
microprocessor complex that includes Drosha, an RNAseIII
enzyme and DGCR8/Pasha, a double stranded RNA-binding
domain protein, to produce a ,70 nucleotide (nt) precursor
miRNA (pre-miRNA). Pre-miRNA is subsequently exported by
Exportin-5 from the nucleus to the cytoplasm, where it is further
processed by the Dicer complex to generate the mature 21–23 nt
miRNA. The two miRNA strands are then separated and the
guide strand is loaded onto the the RNA-induced silencing
complex (RISC) by binding to an Argonaute (Ago) protein
whereas the carrier strand is degraded [1]. The miRNA guides
RISC to complementary sequences within the 3`untranslated
regions (UTR), introns and even exons of a wide range of target
genes. By binding to their complementary sequences, miRNAs
destabilize the corresponding transcripts through mRNA degra-
dation or reduced translation, leading to their silencing.
Because complementary sequences to a given miRNA are found
in numerous genes, a restricted number of miRNAs can regulate
the expression of large numbers of genes, several of which may be
implicated in the control of key cell functions, including
proliferation, differentiation and apoptosis [2]. Not surprisingly,
changes in expression of a host of individual miRNAs have been
associated with various cancer types and implicated in events
ranging from transformation to cancer progression and metastasis.
Because miRNAs repress target gene expression, at least two
miRNA categories that are relevant to oncogenesis have been
identified: those that are overexpressed in cancer cells and act as
oncogenes by targeting tumor suppressive transcripts, and those
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that are repressed in cancer cells and act as tumor suppressor
genes by targeting oncogenic transcripts [3,4]. A mounting body of
evidence suggests that malignant cells display global miRNA
silencing [5]. Recent experimental evidence suggests DICER gene
deletion in mouse models [6] and Dicer protein destabilization in
human cells [7] block miRNA maturation and promote transfor-
mation and tumorigenesis. Downregulation of miRNAs has thus
been associated with diverse types of cancer [1].
Recent work from our laboratory has shown that downregula-
tion of miRNA-145 is implicated in the development of cancer
stem cells (CSC) in Ewing’s sarcoma family tumors (ESFT), the
second most common bone malignancy in children and young
adults [8]. ESFT are characterized by unique chromosomal
translocations that give rise to fusion genes composed of EWS and
one of several ets family members of transcription factors [9]. The
most common fusion gene, EWS-FLI-1, arises as a result of the
chromosomal translocation t(11;22)(q24;q12) and is expressed in
85–90% of ESFT [9]. The EWS-FLI-1 fusion protein is believed
to provide the key oncogenic event in ESFT by inducing and
repressing target genes that lead to transformation of permissive
primary cells. Mesenchymal stem cells (MSC) have been shown to
provide permissiveness for EWS-FLI-1 expression and oncogenic-
ity and are currently considered to be the most likely cell of origin
of ESFT [8,10,11,12].
Despite the identification of their candidate cell of origin, the
mechanisms that underlie ESFT formation are still incompletely
understood. Although EWS-FLI-1 has the ability to directly
modulate the expression of a broad repertoire of target genes,
including induction and repression of oncogenes and tumor
suppressor genes, respectively, these mechanisms do not provide
the full explanation for ESFT pathogenesis.
Based on our recent observations that miRNA-145 repression
underlies the emergence of ESFT CSC [8], we compared the
miRNA expression profiles of MSCs and ESFT cell lines to identify
miRNAs that may be implicated in ESFT pathogenesis and that
may provide potential therapeutic targets. Our observations
indicate that ESFT display concomitant induction of the oncogenic
miRNA 17–92 cluster [13] and repression of the entire let-7 tumor
suppressor family [14,15]. We show the let-7 family member let-7a
to be a direct EWS-FLI-1 target gene, whose in vivo repression
promotes ESFT cell tumorigenicity via induction of its target gene
HMGA2. More importantly, we demonstrate that systemic delivery
of synthetic let-7a significantly decreases tumor growth in vivo,
providing a potentially potent novel therapeutic option in ESFT.
Materials and Methods
Cell culture and retroviral infection
MSCs were isolated and cultured and infected as previously
described [8]. A673 and SK-ES-1 (ATCC), TC252 (kindly provided
by Dr T.Triche [8]) and STA-ET-8.2 (kindly provided by Dr H.
Kovar [16]) ESFT cells lines were cultured in RPMI (Gibco,
Invitrogen) supplemented with 10% FCS (Gibco) and penicillin/
streptamycin (Gibco). A673 and TC252 were infected as previously
described (8). Let-7a vector was kindly provided by Dr R. Agami.
Informed written consent was obtained from all patients involved in
the study and approval was obtained from the ethics committee of
the CHUV and Faculty of Biology and Medicine of the University
of Lausanne. For samples obtained from pediatric patients, written
consent was provided by the parents.
RNA isolation and real-time PCR
Total RNA was isolated using Trifast (Peqlab) according to the
manufacturer’s recommendations. Real time PCR was performed
as previously described [8]. TaqMan probes included: Myc and
Cyclophilin A. SYBR Green gene expression quantification for
HMGA2 primer sequences are Fwd 59-GCGCCTCAGAAGA-
GAGGAC-39 and Rev 59 -GTCTTCCCCTGGGTCTCTTAG-
39, IGF2BP1 primer sequences were: Fwd 59-GGCCTGAGAAT-
GAGTG-39 and Rev 59-GAGGGGCAGACAGTGTTG-39,
hnRNP A1 primer sequences were: Fwd 59-GTCAGCTTG-
CTCCTTTCTGC-39 and Rev 59-GCTCAACCCTCCAAT-
GAAGA-39 Primer sequences for pri-let-7a-1, lin28A and lin28B
were previously described [7] and [17]. For microRNA quanti-
fication, 30ng of total RNA were amplified using miRCURY LNA
Universal RT microRNA PCR kit (Exiqon, DK) according to the
manufacturer’s recommendations. LNA PCR primers from
Exiqon were used for RT-PCR amplification and snord49a was
used as endogenous control.
MicroRNA Array Profiling
RNA quality was assessed by Bioanalyzer. Sample labeling was
performed according to miRXplore User manual (Miltenyi
Biotech). Fluorescence signals of the hybridized miRXplore
Microarrays were detected using a laser scanner from Agilent
(Agilent Technologies). Signal intensity was measured using
ImaGene software (Biodiscovery) and data were analyzed using
the PIQOR Analyzer software. MicroRNAs displaying greater
than a 2-fold change in at least 3 out of the 4 possible comparisons
between the 2 ESFT cell lines and the 2 MSC samples were
considered to be differentially expressed. The 35 microRNA thus
selected (11 up-regulated and 24 down-regulated in ESFT cell
lines compared to MSCs) were used to produce the clustering
shown in Figure 1a. All data are MIAME compliant and the raw
data have been deposited in a MIAME compliant database.
Accession Number: GSE29085.
Chromatin immunoprecipitation
26107 A673 cells were cross-linked with 1% PFA for 10
minutes. PFA was blocked with glycine 125 mM for 5 minutes.
Cells were washed with cold PBS and then scraped on ice with
PBS and proteinase inhibitor (Roche). Cells were lysated in lysis
buffer (1% SDS, 10 mM EDTA, 50 mM Tris HCl pH 8.0) for
10 min and then sonicated to obtain chromatin fragments
between 0.5 to 1 kb length. Cell lysate was diluted 10x in dilution
buffer (1% Triton, 2 mM EDTA, 150 mM NaCl, 20 mM Tris
HCl pH 8.0) and precleared 1 h with prot A sepharose beads (GE
Healthcare Bio-Sciences AB). Samples were incubated overnight
with either anti FLI1 antibody (Santa Cruz Biotechnology) or an
unrelated isotype-matched antibody (Sigma). Protein A sepharose
beads was added for 1 h at 4uC. Beads were washed 3 times with
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
150 mM NaCl, 20 mM Tris HCl pH 8.0) and once with final
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
500 mM NaCl, 20 mM Tris HCl pH 8.0). Chromatin was eluted
with 1% SDS and 100 mM NaHCO3 for 15 min. Reverse cross-
linking was performed at 65uC for 4 h and proteins were digested
with proteinase K for 1 h at 45uC. Chromatin was recovered using
phenol/chloroform extraction. For real time PCR the following
primers were used: Fwd let-7a-1 promoter 59 TGTGGCTATA-
CAGCCGTCAG 39 and Rev let-7a-1 promoter 59ACCCATA-
CATGGGTCAACTG 39. For non-specific binding region
previously published primer sequences were used [18].
Luciferase assay
Let-7a-1 promoter was amplified from genomic DNA from
hpMSC and cloned into pGL3 luciferase vector (Promega) using
the following primer sequences: Fwd KpnI 59-GGGGTACC-
let-7a Regulates ESFT Development
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23592
CCTGTGTGTTTTGCACACCAGTTTAC-39 and Rev NheI
59 –CTAGCTAGCTAGAGTGAAGAGAACATCCAGGGT-
GAATG-39. HEK-293T cells were co-transfected with empty
pGL3 or let-7a-1 promoter pGL3 vector along with pMSCV
empty or pMSCV EWS-FLI-1-V5 vector and renilla vector using
Fugene (Roche). 48 h after transfection luciferase and renilla
activity were measured using Dual-lucifease Reporter assay system
(Promega) according to manufacturer’s instructions.
Figure 1. miRNAs expression in ESFT. A) Clustering of MSC, A673 and TC252 ESFT cell lines according to expression levels of the 35 differentially
expressed microRNAs. B) Left: Real-Time PCR analysis of let-7 family expression in MSC, A673, TC252, STA-ET-8.2, SK-ES-1 cells and primary ESFT.
Right: Real-Time PCR analysis of miRNA-100 and miRNA-125b in MSC, A673, TC252 cells and primary ESFT. C) Real-Time PCR analysis of miRNA-17–92
cluster and its paralogs in MSC, A673, TC252 cells and primary ESFT. Real-Time PCR experiments were normalized to SNORD49A, and done in
triplicate. Error bars represent the SD of three independent experiments. Student T-test was used for statistical analysis. * p,0.05, ** p,0.005,
*** p,0.0005.
doi:10.1371/journal.pone.0023592.g001
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HMGA2 construct, HMGA2 and EWS-FLI-1 depletion
HMGA2 was amplified from A673 cDNA and cloned into
pMSCV puro vector (Clonetech) using the following primer
sequences: Fwd BglII 59- GAAGATCTTCCCACCATGAGCG-
CACGCGGTGAGGG-39 and Rev EcoRI 59- GGAATTCCT-
CAGTGACTCCTTTTGGTACTGTTTC-39.Sequences #1 and
#2 for stable knock-down of HMGA2 are respectively: 59-
CGGCCAAGAGGCAGACCTA - 39 and 59- GCGCCAACGTTC-
GATTTCT - 39. The sequence for stable EWS-FLI-1 knock-down
was previously described [12]. Oligonucleotides were annealed and
cloned in pSiren RetroQ vector (Clontech).
Western blot analysis
Western blot was performed as previously described [8].
Antibodies used for the study were anti-: c-Myc (Santa Cruz
Biotechnology), HMGA2 (Biocheck, Inc. Foster City, CA),
IGF2BP1 (Cell Signaling), Lin28B (Cell Signaling), Fli-1 (Santa
Cruz Biotechnology) and b-actin (Sigma). Densitometric quanti-
fication was performed using Image J software.
Tumorigenicity assay
NOD-SCIDmice were anesthetized and 16106 or 26106 A673 or
TC252 cells respectively were injected subcutaneously. The animals
were sacrificed 4 weeks after injection. All tumors were resected at
autopsy and sectioned for histological analysis. For in vivo treatment
assay, 30 mg of miScript microRNA mimic (Qiagen) was formulated
with MaxSuppressor in vivo RNALancerII (BIOO Scientific, Inc),
according to the manufacturer recommendations. MiRNAs were
administrated intravenously by tail vein injection at day 11, 14, and
17. Tumor volume was measured as previously described [19].
Experimental protocols involving mice were approved by the Etat de
Vaud, Service Ve´te´rinaire, authorization number VD1477.2.
MTT assay
MTT assays were performed according to standard procedures.
Immunohistochemistry
Paraffin-embedded sections of primary Ewing’s sarcoma,
TC252- and A673-derived tumors were stained with rabbit anti-
human HMGA2 polyclonal antibody (Biocheck) or rabbit anti-
human Lin28B polyclonal antibody (Cell Signaling). Horseradish
peroxidase staining was performed using biotin conjugated goat
anti-rabbit (Vector Laboratories), and was revealed with a DAKO
DAB Kit (Dako).
Results
Expression profile comparison of ESFT cell lines to MSC
identify a restricted cluster of differentially expressed
miRNAs in ESFT
To identify miRNAs that may be involved in ESFT development
we performed miRNA expression profiling of MSCs and two ESFT
cell lines (A673 and TC252). A673 and TC252 were chosen because
they bear a different p53 status, the latter having been shown to
influence miRNA maturation [20]. A673 cells harbor mutated p53
whereas TC252 cells express the wt form [21]. The two ESFT cell
lines revealed a similar miRNA expression profile, characterized by
repression of the entire let-7 family, miRNA-100, miRNA-125b and
miRNA-31, and over-expression of the miRNA 17–92 cluster and
its paralogs miRNA-106a and miRNA-106b (Figure 1A). The
expression status of these miRNAs was validated by qRT-PCR in 3
primary ESFT and four ESFT cell lines (A673, TC252, STA-ET-
8.2 and SK-ES-1, Figure 1B, C and Figure S1A). The observed
changes in miRNA expression are consistent with reports that
members of the let-7 family are repressed in a broad range of tumors
[14], that miRNA-31 is repressed in disseminating and metastatic
malignancies [22,23] and that overexpression of the cluster 17–92 is
involved in the tumorigenic phenotype of haematologic malignan-
cies as well as that of a variety of solid tumors [13].
Let-7a is a direct EWS-FLI-1 target implicated in ESFT cell
tumorigenicity
Members of the let-7 family play a major role in cell
differentiation and are considered to act as tumor suppressors by
silencing numerous genes that encode oncogenic proteins
including HMGA2, insulin-like growth factor 2-binding protein 1
(IGF2BP1), RAS and c-MYC [24,25]. Although low expression of
all the let-7 family members was observed in primary ESFT cells
and ESFT cell lines compared to MSCs (Figure 1A), we focused
our attention on let-7a because its repression has been shown to be
directly implicated in the pathogenesis of several cancer types as
well as in maintenance of breast cancer CSC [15,26]. Moreover,
despite the ability of EWS-FLI-1 to directly induce expression of c-
Myc, a known regulator of let-7 expression, recent evidence
suggests that let-7a may also constitute a direct EWS-FLI-1 target
gene [27], further supporting possible involvement of let-7a in
ESFT development. To verify this notion, we performed
chromatin immunoprecipitation (ChIP) in A673 cells using anti-
Fli-1 antibody and observed a five-fold enrichment of the let-7a-1
promoter region, compared to the isotype-matched control
antibody, as assessed by Real-Time PCR analysis, indicating that
EWS-FLI-1 directly binds to the let-7a-1 promoter (Figure 2A,
left). To determine the functional consequence of the observed
binding we engineered a luciferase reporter vector that expresses
the luciferase gene under the control of the let-7a-1 promoter.
Luciferase activity was reduced by 50% upon EWS-FLI-1
expression in HEK-293T cells, indicating that EWS-FLI-1 is able
to repress let-7a-1 promoter activity in vivo (Figure 2A, right). To
further verify the ability of EWS-FLI-1 to repress let-7a at the
transcriptional level, we introduced EWS-FLI-1 into human
pediatric MSC cultured in serum free medium by retroviral
infection as previously described (8). Expression of EWS-FLI-1
resulted in reduction of pri-let-7a-1 and mature let-7a expression
(Figure 2B). Real-Time PCR comparison of the pri-let-7a-1
transcript in MSCs, ESFT cell lines and primary ESFT revealed
decreased expression in all ESFT cell lines tested as well as in
primary ESFT (Figure S1B), supporting the notion that EWS-FLI-
1 directly represses let-7a promoter activity in vivo. To further
validate the observed repression of the let-7a-1 promoter by EWS-
FLI-1, we silenced EWS-FLI-1 in A673 using an shRNA
approach. Five days following EWS-FLI-1 silencing upregulation
of the pri-let-7a-1 transcript as well as mature let-7a was recorded
(Figure 2C). These observations explain, at least in part, the low
let-7a transcript levels observed in Ewing’s sarcoma cells.
Expression of the let-7 family is also known to be tightly regulated
at the post-transcriptional level by LIN28, a direct let-7 target gene
[28,29,30]. Lin28 is an RNA-binding protein highly expressed in
embryonic stem and progenitor cells as well as in a wide range of
human cancers but not in most adult tissues. Lin28 is strongly
implicated in the induction and control of pluripotency and binds to
the terminal loops of let-7 precursors, thereby blocking their
processing to mature forms [30]. To determine whether lin28 may
also participate in the regulation of let-7 expression in ESFT, we
compared the expression levels of LIN28A and LIN28B in MSC,
ESFT cell lines and primary tumors. No significant difference in
LIN28A expression was observed (data not shown), whereas LIN28B
was more highly expressed in ESFT cell lines than in MSC
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Figure 2. let-7a is a direct target of EWS-FLI-1. A) Left: Upper panel: 1 kb genomic region encompassing the let-7a-1 locus. Blue bar: genomic
region coding for the precursor let-7a-1, red bar: genomic region containing the putative let-7a-1 promoter, as identified by Gangwal and al [27].
Lower panel: Real-Time PCR analysis of anti-Fli-1 or isotype-matched control antibody immunoprecipitated chromatin in A673 cells showing a 5-fold
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(Figure 2D). Recently hnRNP A1 has been shown to bind to the
terminal loop of pri-let-7a-1 and impair its maturation [31]. To
determine whether hnRNP A1 might participate in the blockade of
pri-let-7a-1 maturation, we measured by Real-Time PCR the
expression level of hnRNP A1 inMSC, ESFT cell lines and primary
ESFT. Higher expression of hnRNP A1 in ESFT cell lines and
primary tumors was observed compared to MSC (Figure 2E).
Taken together these results suggest that in ESFT let-7a is subject to
a triple repressive regulatory mechanism at both transcriptional and
post-transcriptional levels as a result of direct binding of EWS-FLI-1
to its promoter and lin28B-hnRNP A1-mediated maturation
blockade, respectively.
Because let-7a has been widely described as a tumor suppressor
miRNA, we investigated its putative role in ESFT development. To
this end, let-7a was overexpressed in the two ESFT cell lines (A673
and TC252) using a retroviral system, which resulted in a 2.5 fold
increase in its expression (Figure 3A). Cell proliferation was almost
unaffected, as assessed by MTT assay (Figure 3B). Six NOD/SCID
mice were then injected subcutaneously with 16106 or 26106 let-
7a-expressing or empty vector-infected A673 and TC252 cells,
respectively, and tumor formation was assessed weekly for four
weeks, whereupon the animals were sacrificed. Although all mice
developed tumors, even moderate let-7a overexpression resulted in
a marked decrease in tumor volume irrespective of their cell line
derivation (Figure 3C), consistent with findings in other tumor types,
where let-7 expression was reported to delay tumor growth [19].
These observations indicate that direct repression of the let-7a
promoter activity exerted by EWS-FLI-1 contributes to ESFT
development. The discrepancy between the lack of any significant
effect of let-7a expression on proliferation and its potent inhibition
of tumor growth is not surprising, as decreased stemness coupled to
reduced tumor initiating potential that should result from let7a
expression may be independent of cell division.
The let-7a target gene HMGA2 promotes tumorigenicity
in ESFT cells
To gain insight into the mechanism whereby let-7a over-
expression inhibits ESFT growth, expression levels of a panel of
established let-7a target genes known to display oncogenic
properties, including HMGA2, IGF2BP1, c-MYC and LIN28B,
were assessed by Real-Time PCR in empty-vector infected and let-
7a-transduced A673 and TC252 cells (Figure 3D). Significant
reduction in HMGA2, IGF2BP1 and LIN28B expression at both the
mRNA and protein levels was observed in both cell lines upon let-
7a over-expression, whereas c-MYC expression was mildly affected
in TC252 but not A673 cells (Figure 3D, 3E and data not shown).
Among the genes that we found to be repressed upon let-7a
expression in ESFT cell lines, we focused on HMGA2 because of its
recognized role as an oncogene in a variety of human tumors [32].
HMGA2 is a DNA binding protein highly expressed in embryonic
stem cells and cancer cells but undetectable in most normal adult
tissues. It functions to alter chromatin structure in order to
regulate expression of its target gene repertoire by enhancing or
suppressing the activity of a variety of transcription factors [32].
HMGA2 has been found to be frequently expressed in benign
mesenchymal tumors, including lipomas and leiomyomas, and to
be amplified or rearranged in both well and poorly differentiated
liposarcomas [33]. Immunohistochemical analysis showed strong
nuclear HMGA2 expression in primary ESFT and both A673 and
TC252 cell line-derived tumors (Figure 4A). To determine
whether the reduction in tumor growth displayed by let-7a-
expressing tumor cells may be at least in part mediated by the
concomitant decrease in HMGA2 expression, we used an shRNA
approach to deplete HMGA2 expression in A673 and TC252
cells. Retroviral vectors expressing two independent shRNA
sequences targeting HMGA2 were used to infect A673 and
TC252 cells, and a vector containing an unrelated shRNA
sequence was used as control. The resulting HMGA2 knock-down
efficiency of about 70% was similar to the effect of let-7a
overexpression in the same cells, as assessed by Real-Time PCR
and Western Blot analysis (Figure 4B). Depletion of HMGA2
minimally affected cell proliferation, as assessed by MTT assays
(Figure S1C left). However, subcutaneous injection of HMGA2-
depleted A673 and TC252 cells into NOD-SCID mice resulted in
markedly reduced tumor growth, mimicking the effect of let-7a
overexpression (Figure 4C and Figure S1C right). To verify that
the reduction of tumor growth associated with let-7a expression
was HMGA2-dependent, we performed a rescue experiment
where the cDNA encoding HMGA2 lacking its endogenous 39
UTR was expressed in A673 and TC252 cells prior to their
infection with the let-7a-expressing retrovirus. Because of the lack
of the 39 UTR that contains the let-7a binding sites, exogenous
cDNA-mediated expression of HMGA2 should remain unaffected
by let-7a expression whereas endogenous transcripts should be
silenced. Real-Time PCR and Western Blot analysis confirmed
that HMGA2-infected A673 and TC252 cells expressed higher
HMGA2 transcript and protein levels than empty vector infected
cells (Figure 4D and data not shown). Importantly, however,
HMGA2 expression in these cells returned to the pre-infection
wild-type baseline level upon let-7a expression, consistent with
selective silencing of the endogenous transcripts (Figure 4D and
data not shown). A673 and TC252 cells expressing HMGA2
alone, let-7a alone or the combination of the two genes were
injected subcutaneously into NOD/SCID mice, and the tumor
forming ability of the different cell populations compared to that of
their empty vector-infected counterparts. HMGA2-expressing cells
failed to show any significant difference in tumor forming capacity
compared to control cells. By contrast, let-7a only expressing cells
displayed decreased tumorigenicity that was restored in cells
expressing both HMGA2 and let-7a transcripts (Figure 4D and
Figure S1D). To confirm that expression of HMGA2 was altered
in let-7a expressing cell-derived tumors we assessed its expression
by immunohistochemical staining in ESFT cell line-derived
tumors. Consistent with the notion that HMGA2 is a target of
let-7a expression of HMGA2 was decreased in tumors derived
from let-7a expressing ESFT cells (Figure S2A). These observa-
tions uncover the important effector role of HMGA2 in ESFT cell
tumorigenicity and identify let-7a-mediated repression of HMGA2
as a key mechanism in the reduction of tumor forming capacity by
tumor cells upon let-7a restoration.
enrichment of the let-7a-1 promoter with anti-Fli-1 antibody. Right: let-7a-1 promoter luciferase assay showing EWS-FLI-1-mediated repression of
luciferase activity in HEK-293T cells (upper panel), and expression of the EWS-FLI-1 fusion protein in the corresponding cell population (lower panel).
B) Real-Time PCR analysis of pri-let-7a-1 and mature let-7a expression in human pediatric MSCEWS-FLI-1. C) Real-Time PCR analysis of pri-let-7a-1 and
mature let-7a in EWS-FLI-1-depleted A673. D) Western blot analysis of LIN28B expression in MSC, ESFT cell lines and PA-1 teratocarcinoma cell line. E)
Real-Time PCR analysis of hnRNP A1 expression in MSC, ESFT cell lines and primary ESFT. Real-Time PCR experiments were normalized to Cyclophilin
A, and done in triplicate. Error bars represent the SD of three independent experiments. Student T-test was used for statistical analysis.* p,0.05,
** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0023592.g002
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Synthetic let-7a decreases ESFT growth in vivo
Our observations thus far prompted us to assess the effectiveness
of administering let-7a to block ESFT growth. Feasibility of
miRNA-based therapy has been demonstrated for both primary[34]
and metastatic tumor growth [35]. A variety of approaches have
been used to administer miRNA, including intra-tumoral and intra-
venous injection. We selected to deliver miRNAs into the
bloodstream of mice bearing tumors because it corresponds to the
principal mode of chemotherapeutic drug administration. A673
cells were injected subcutaneously into NOD-SCID mice and let-7a
was administered once tumors reached a volume of 60 mm3. 30 mg
of synthetic miRNA, corresponding to a concentration of 1.5 mg/g,
were injected into the tail vein in a single bolus on days 11, 14 and
17 post tumor cell grafting and tumor volume was measured every
three days starting from the first injection. Marked reduction of
tumor growth in mice treated with synthetic let-7a was observed
(Figure 5A). To verify that the observed reduction of tumor growth
was the consequence of exogenous miRNA administration we
performed Real-Time PCR comparison of let-7a expression
between treated and control tumors. Let-7a expression was found
to be increased in treated tumors compared to their control
counterparts, confirming that the injected synthetic miRNAs had
reached the developing tumors (Figure 5B). To formally demon-
strate that the delivered miRNA had been incorporated into the
target tumor cells, we assessed the expression of HMGA2 and
LIN28B by Real-Time PCR, immunohistochemical staining and
Western blot analysis and observed a decrease in both transcript
and protein levels in let-7a-treated tumors (Figure 5C and Figure
S2B). Heterogeneous expression of HMGA2 and lin28B was
observed in let-7a-treated tumors suggesting non uniform distribu-
tion of synthetic miRNA within the tumor.
Discussion
We have previously identified miRNA-145 as a direct EWS-
FLI-1 target gene, whose repression is implicated in ESFT
development, suggesting that other miRNAs may be involved in
the pathogenesis of these tumors. Using miRNA array profiling we
uncovered a limited number of differentially expressed miRNA
families in ESFT cells. Among induced miRNAs, we found the
oncogenic miRNA 17–92 cluster and its paralogs miRNA106a/b,
whereas repressed miRNAs included miRNA 100, 125b as well as
the entire let-7 family. Interestingly, the miRNA 17–92 cluster has
been reported to be directly induced by c-Myc, a known EWS-
FLI-1 target gene [36], suggesting that this cluster may be
indirectly modulated by EWS-FLI-1 through c-Myc induction.
Among the let-7 miRNA family we focused on let-7a because of its
reported functional role in diverse cancer types.
Let-7a repression and the corresponding upregulation of
its target gene HMGA2 provide a new mechanism of
sustained ESFT growth
Let-7a repression has been observed in diverse malignant tumor
types, including a variety of sarcomas and carcinomas. Let-7a
down-regulation is mediated by several mechanisms including
Lin28-dependent degradation (27–29) and myc-dependent tran-
scriptional repression [37]. In ESFT, we have shown that direct
EWS-FLI-1-mediated repression provides a novel regulatory
mechanism of let-7a expression. Given its role as an inhibitor of
differentiation [38], let-7a repression may participate in early
EWS-FLI-1-mediated transformation, by enhancing primary cell
permissiveness for EWS-FLI-1 expression and function, as well as
in subsequent ESFT CSC maintenance. The observed upregula-
tion of the stem cell gene LIN28B in ESFT is consistent with its
reported function as an oncogene whose expression in human
cancer is associated with unfavorable prognosis [17]. LIN28 is an
RNA binding protein whose expression is normally restricted to
embryonic stem and progenitor cells as well as developing tissues,
where it plays the role of a master regulator of pluripotency.
Together with OCT-4, SOX2 and NANOG, LIN28 is also
involved in genetic reprogramming that leads to generation of
induced pluripotent stem cells (iPS) in vitro [39]. Reactivation of its
expression may therefore constitute one of the mechanisms that
links genetic reprogramming to CSC emergence in human
tumors. LIN28 has recently been shown to be directly involved
in the generation and maintenance of ovarian aldehyde dehydro-
genase (ALDH)-positive CSC through its ability to block let-7
maturation [40]. Together with increasing evidence of a pivotal
role of let-7 in normal and cancer stem cell differentiation, this
observation further supports the notion that the double negative
feedback loop between LIN28 and let-7 may regulate the behavior
of CSC in vivo. In the context of the recent report that ESFT CSC
express high ALDH levels [41], it is tempting to speculate that let-
7a and miRNA-145 repression may play a critical role in EWS-
FLI-1-mediated CSC generation. Similar to our discovery that
repression of miRNA-145 is directly involved in the emergence of
ESFT CSC [8], the observed repression of let-7a may enhance
expression of LIN28B, triggering a double negative feed-back loop
that reinforces let-7 repression in ESFT and facilitates CSC
generation and maintenance.
Let-7a target genes relevant to transformation and subsequent
tumor development include RAS, MYC, IGF2BP1 and HMGA2.
HMGA2 is of particular interest in ESFT because its overexpres-
sion is associated with both benign and malignant mesenchymal
tumors [42] and because it has been shown to regulate
mesenchymal stem cell genes [43]. HMGA2 is a DNA binding
protein that does not have transcriptional activity but rather
cooperates with the transcription machinery to alter chromatin
structure, thereby inducing or silencing numerous genes. Among
its known functions are induction of E2F activity, cyclin A and
pro-inflammatory protein expression, modulation of miRNA
expression as well as genes implicated in epithelial to mesenchymal
transition and inhibition of p53-mediated apoptosis [32]. In ESFT
cells, HMGA2 depletion resulted in markedly reduced tumor
growth, consistent with a role in CSC maintenance by a variety of
possible mechanisms that include inhibition of the oncogenic stress
response to EWS-FLI-1, promotion of stemness as a consequence
of chromatin modification and maintenance of cell cycle. In
support of this notion, HMGA2 has been recently reported to
participate in self-renewal of neural stem cells by controlling the
INK4A locus [44]. Thus by virtue of its selective overexpression in
Figure 3. let-7a blocks ESFT tumor growth. A) Left: Real-Time PCR analysis of let-7a overexpression in the A673 and TC252 ESFT cell lines. B)
MTT proliferation assay of mock-infected and let-7a-overexpressing A673 and TC252 cells. C) let-7a overexpression in A673 (left panel) and TC252
(right panel) tumor cells leads to a significant decrease in their tumorigenicity. D) Real-Time PCR analysis of let-7a target genes HMGA2, IGF2BP1, c-
MYC and LIN28B expression in mock-infected and let-7a-overexpressing A673 and TC252 cells. E) Western Blot analysis showing reduction of HMGA2
and IGF2BP1 expression of in let-7a overexpressing A673 and TC252 cells. Real-Time PCR experiments were normalized to either Cyclophilin A for
mRNA or SNORD49A for miRNAs, and done in triplicate. Error bars represent the SD of three independent determinations. Student T-test was used for
statistical analysis.* p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0023592.g003
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Figure 4. let-7a overexpression-associated loss of tumorigenicity is HMGA2-dependent. A) Immunohistochemical assessment of HMGA2
expression in primary ESFT and A673 and TC252 cell line-derived tumors grown in immunocompromised mice. Magnification 100x. B) Real-Time PCR
(left panel) and Western blot analysis (right panel) of HMGA2 depletion in A673 and TC252 cells. C) Depletion of HMGA2 in A673 cells reduces
corresponding tumor growth. D) Upper panel: Western blot analysis of HMGA2 expression in A673 cells transduced with empty vector, let-7a alone,
let-7a and HMGA2 or HMGA2 alone. Lower panel: HMGA2 expression in A673 cells overexpressing let-7a rescues their tumorigenic properties. Real-
Time PCR experiments were normalized to Cyclophilin A, and done in triplicate. Error bars represent the SD of three independent experiments.
Student T-test was used for statistical analysis.* p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0023592.g004
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tumor cells and likely role in CSC maintenance, HMGA2 may
constitute a therapeutic target of interest.
Targeting of selected miRNA provides a means to control
ESFT growth
Reversion of miRNA suppression mechanisms in CSC could
conceptually lead to abrogation of their stem cell properties and
elimination of their tumor repopulating capacity. However, this
would require in depth understanding of the mechanisms involved,
which, as is increasingly apparent, may be multiple with uncertain
targetability [1,7]. An alternative approach is to restore relevant
miRNA expression by systemic administration of synthetic
miRNA in vivo. Synthetic miRNAs have the advantage of being
easy to engineer and of being stable. More importantly, miRNA
administration may be devoid of major secondary effects as
differentiated cells already express high miRNA levels to which
administration of exogenous species is unlikely to contribute in
significant fashion. Thus, exogenous miRNA administration can
selectively replenish cells that display inappropriate miRNA
repression associated with disease. Our observations demonstrate
the feasibility of reducing ESFT growth in vivo by administering
relatively low doses of synthetic let-7a. Moreover, they provide
evidence of miRNA delivery to the appropriate tumor target cells
and their effect within the cells as illustrated by the expected
alteration in target gene expression levels.
Taken together, our observations have identified a miRNA
expression signature that characterizes ESFT and that participates
in ESFT pathogenesis, including the miRNA tumor suppressor
family let-7. We have also shown that EWS-FLI-1 directly binds to
the let-7a promoter, repressing its transcriptional activity, and that
reduced let-7a expression is implicated in ESFT development
through HMGA2 regulation. Finally, restoration of let-7a
expression by an approach as simple as in vivo systemic delivery
of synthetic miRNAs may provide the means to control
malignancies as aggressive as ESFT.
Supporting Information
Figure S1 miRNA expression in STA-ET-8.2 and SK-ES-
1 ESFT cell lines, MTT and tumorigenic assay of
HMGA2-depleted TC252 tumor cells. A) Real-Time PCR
Figure 5. Systemic let-7a delivery reduces ESFT tumor growth in vivo. A) Tail vein injection of 30 mg of synthetic let-7a reduces the growth
of established ESFT tumors. Let-7a was administered on days 11, 14 and 17 following the initial subcutaneous injection of A673 tumor cells. Mice
were sacrificed on day 22 and tumor size assessed. B) Real-Time PCR analysis of let-7a expression in A673-treated or control tumors. C) Left: Real-
Time PCR analysis of HMGA2 and LIN28B expression in A673-treated or control tumors. Right: immunohistochemical staining of HMGA2 and Lin28B
in A673-treated or control tumors. Magnification 100x. Real-Time PCR experiments were normalized to SNORD49a or Cyclophilin A, and done in
triplicate. Error bars represent the SD of three independent determinations. Student T-test was used for statistical analysis.* p,0.05.
doi:10.1371/journal.pone.0023592.g005
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analysis of miRNA-100, miRNA-125b in MSC, STA-ET-8.2 and
SK-ES-1 cells. B) Real-Time PCR analysis of pri-let-7a-1
expression in MSC, ESFT cell lines and primary ESFT. C) Left:
MTT assay of mock-infected and HMGA2-depleted ESFT tumor
cells. Right: Depletion of HMGA2 in TC252 cells reduces
corresponding tumor growth. D) HMGA2 expression in TC252
cells overexpressing let-7a rescues their tumorigenic properties.
Error bars represent the SD of three independent determinations.
Student T-test was used for statistical analysis, ** p,0.005,
*** p,0.0005.
(TIF)
Figure S2 HMGA2 and Lin28 expression in let-7a and
let-7a-HMGA2 expressing ESFT cells derived tumors. A)
Immunohistochemical staining of HMGA2 in mock- let-7a and
let-7a-HMGA2 expressing ESFT cell lines derived tumors. B)
Western blot analysis of tumors from mice treated with let7a and
vehicle only. Magnification 100x.
(TIF)
Author Contributions
Conceived and designed the experiments: CDV NR IS. Performed the
experiments: CDV NR KB JH. Analyzed the data: CDV NRM-LS MJ PP .
Contributed reagents/materials/analysis tools: MJ. Wrote the paper: CDV
NR IS.
References
1. Melo SA, Esteller M (2011) Dysregulation of microRNAs in cancer: Playing with
fire. FEBS Lett 585: 2087–2099.
2. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell
136: 215–233.
3. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way.
Cell 136: 586–591.
4. Plasterk RH (2006) Micro RNAs in animal development. Cell 124: 877–881.
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA
expression profiles classify human cancers. Nature 435: 834–838.
6. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA
processing enhances cellular transformation and tumorigenesis. Nat Genet 39:
673–677.
7. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, et al. (2009) A
TARBP2 mutation in human cancer impairs microRNA processing and
DICER1 function. Nat Genet 41: 365–370.
8. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, et al. (2010) EWS-FLI-1
modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell
reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 24:
916–932.
9. Riggi N, Stamenkovic I (2007) The Biology of Ewing sarcoma. Cancer Lett 254:
1–10.
10. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, et al. (2005) Development
of Ewing’s sarcoma from primary bone marrow-derived mesenchymal
progenitor cells. Cancer Res 65: 11459–11468.
11. Riggi N, Suva ML, Suva D, Cironi L, Provero P, et al. (2008) EWS-FLI-1
expression triggers a Ewing’s sarcoma initiation program in primary human
mesenchymal stem cells. Cancer Res 68: 2176–2185.
12. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, et al. (2007)
Mesenchymal stem cell features of ewing tumors. Cancer Cell 11: 421–429.
13. Mendell JT (2008) miRiad roles for the miR-17-92 cluster in development and
disease. Cell 133: 217–222.
14. Bussing I, Slack FJ, Grosshans H (2008) let-7 microRNAs in development, stem
cells and cancer. Trends Mol Med 14: 400–409.
15. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal
and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.
16. Jiang X, Gwye Y, Russell D, Cao C, Douglas D, et al. (2010) CD133 expression
in chemo-resistant Ewing sarcoma cells. BMC Cancer 10: 116.
17. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, et al. (2009) Lin28
promotes transformation and is associated with advanced human malignancies.
Nat Genet 41: 843–848.
18. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, et al. (2009) EZH2 is a
mediator of EWS/FLI1 driven tumor growth and metastasis blocking
endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A
106: 5324–5329.
19. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, et al. (2008)
The let-7 microRNA reduces tumor growth in mouse models of lung cancer.
Cell Cycle 7: 759–764.
20. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, et al. (2009)
Modulation of microRNA processing by p53. Nature 460: 529–533.
21. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, et al. (1997) Among genes
involved in the RB dependent cell cycle regulatory cascade, the p16 tumor
suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15:
2225–2232.
22. Valastyan S, Weinberg RA (2010) miR-31: A crucial overseer of tumor
metastasis and other emerging roles. Cell Cycle 9.
23. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al. (2009) A
pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell
137: 1032–1046.
24. Boyerinas B, Park SM, Shomron N, Hedegaard MM, Vinther J, et al. (2008)
Identification of let-7-regulated oncofetal genes. Cancer Res 68: 2587–2591.
25. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, et al. (2008)
Suppression of non-small cell lung tumor development by the let-7 microRNA
family. Proc Natl Acad Sci U S A 105: 3903–3908.
26. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME (2010) The role of let-7
in cell differentiation and cancer. Endocr Relat Cancer 17: F19–36.
27. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, et al. (2008)
Microsatellites as EWS/FLI response elements in Ewing’s sarcoma. Proc Natl
Acad Sci U S A 105: 10149–10154.
28. Newman MA, Thomson JM, Hammond SM (2008) Lin-28 interaction with the
Let-7 precursor loop mediates regulated microRNA processing. RNA 14:
1539–1549.
29. Viswanathan SR, Daley GQ, Gregory RI (2008) Selective blockade of
microRNA processing by Lin28. Science 320: 97–100.
30. Heo I, Joo C, Cho J, Ha M, Han J, et al. (2008) Lin28 mediates the terminal
uridylation of let-7 precursor MicroRNA. Mol Cell 32: 276–284.
31. Michlewski G, Caceres JF (2010) Antagonistic role of hnRNP A1 and KSRP in
the regulation of let-7a biogenesis. Nature structural & molecular biology 17:
1011–1018.
32. Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer
7: 899–910.
33. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, et al. (2008)
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated
liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
Int J Cancer 122: 2233–2241.
34. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, et al. (2010)
Development of a lung cancer therapeutic based on the tumor suppressor
microRNA-34. Cancer Res 70: 5923–5930.
35. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, et al. (2010) Therapeutic
silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat
Biotechnol 28: 341–347.
36. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-
regulated microRNAs modulate E2F1 expression. Nature 435: 839–843.
37. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, et al. (2008) Widespread
microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40:
43–50.
38. Droge P, Davey CA (2008) Do cells let-7 determine stemness? Cell Stem Cell 2:
8–9.
39. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al.
(2007) Induced pluripotent stem cell lines derived from human somatic cells.
Science 318: 1917–1920.
40. Yang X, Lin X, Zhong X, Kaur S, Li N, et al. (2010) Double-Negative Feedback
Loop between Reprogramming Factor LIN28 and microRNA let-7 Regulates
Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells. Cancer Res 70:
9463–9472.
41. Awad O, Yustein JT, Shah P, Gul N, Katuri V, et al. (2010) High ALDH
Activity Identifies Chemotherapy-Resistant Ewing’s Sarcoma Stem Cells That
Retain Sensitivity to EWS-FLI1 Inhibition. PLoS One 5: e13943.
42. Dreux N, Marty M, Chibon F, Velasco V, Hostein I, et al. (2010) Value and
limitation of immunohistochemical expression of HMGA2 in mesenchymal
tumors: about a series of 1052 cases. Mod Pathol.
43. Henriksen J, Stabell M, Meza-Zepeda LA, Lauvrak SA, Kassem M, et al. (2010)
Identification of target genes for wild type and truncated HMGA2 in
mesenchymal stem-like cells. BMC Cancer 10: 329.
44. Nishino J, Kim I, Chada K, Morrison SJ (2008) Hmga2 promotes neural stem
cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf
Expression. Cell 135: 227–239.
let-7a Regulates ESFT Development
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23592
